Loading...
Back to narrative

HYPR: India Approval And New MRI Software Will Drive Strong Upside Potential

Supply Disruptions And Delayed Adoption Will Undermine Long-Term Outlook

HYPR logo
HYPR
AnalystLowTarget
Not Invested
Published 15 Aug 2025

Update shared on 18 Dec 2025

Fair value Increased 53%
n/a
n/a
AnalystLowTarget's Fair Value
n/a
Loading
1Y
24.3%
7D
10.5%

Analysts have raised their price target on Hyperfine from approximately $0.85 to $1.30 per share, citing stronger projected revenue growth, slightly improved profit margins, and a higher expected future P E multiple, despite a modest uptick in the assumed discount rate.

What's in the News

  • Hyperfine received regulatory approval from India's Central Drugs Standard Control Organization to commercialize its Swoop portable MRI system nationally, opening access to advanced brain imaging in a large, under-served market (Key Developments).
  • The company secured FDA clearance for a new multi-direction diffusion-weighted imaging software sequence for Swoop, enhancing image quality and diagnostic confidence in stroke detection (Key Developments).
  • Hyperfine launched the PRISM PMR study to evaluate Swoop's use in neurosurgical operating rooms, focusing on detecting post-operative complications and enabling faster discharge and recovery (Key Developments).
  • The company introduced PULSE, a subscription-based platform that gives Swoop users access to research sequences, raw data, and developer tools to accelerate innovation in portable MRI (Key Developments).
  • Management issued updated guidance, projecting fourth quarter 2025 revenue of approximately $5 million to $6 million and full year 2025 revenue of about $13 million to $14 million (Key Developments).

Valuation Changes

  • Fair Value: Increased moderately from approximately $0.85 to $1.30 per share. This reflects a higher estimated intrinsic value for Hyperfine's equity.
  • Discount Rate: Risen slightly from about 7.47 percent to 7.67 percent. This indicates a modestly higher assumed risk or required return.
  • Revenue Growth: Increased significantly from roughly 30.86 percent to 49.09 percent. This signals materially stronger expectations for future sales expansion.
  • Net Profit Margin: Improved slightly from around 12.49 percent to 12.91 percent. This suggests modestly better long term profitability assumptions.
  • Future P E: Increased meaningfully from about 33.52 times to 42.62 times. This indicates a higher assumed valuation multiple on forward earnings.

Have other thoughts on Hyperfine?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.